Aim. ough combination of clopidogrel added to aspirin has been compared to aspirin alone in patients with stroke or transient ischemic attack, limited data exists on the relative efficacy and safety between clopidogrel and aspirin monotherapy in patients with a recent ischemic stroke. We aimed to compare clopidogrel versus aspirin monotherapy in this population. Methods. PubMed, Embase, and CENTRAL databases were searched from inception to May 2018 to identify clinical trials and observational studies comparing clopidogrel versus aspirin for secondary prevention in patients with recent ischemic stroke within 12 months. Pooled effect estimates were calculated using a random effects model and were reported as risk ratios with 95% confidence intervals. Results. Five studies meeting eligibility criteria were included in the analysis. A total of 29,357 adult patients who had recent ischemic stroke received either clopidogrel (푛 = 14, 293) or aspirin (푛 = 15, 064) for secondary prevention. Pairwise meta-analysis showed a statistically significant risk reduction in the occurrence of major adverse cardiovascular and cerebrovascular events (risk ratio 0.72 [95% CI, 0.53-0.97]), any ischemic or hemorrhagic stroke (0.76 [0.58, 0.99), and recurrent ischemic stroke (0.72 [0.55, 0.94]) in patients who received clopidogrel versus aspirin. e risk of bleeding was also lower for clopidogrel versus aspirin (0.57 [0.45, 0.74]). ere was no difference in the rate of all-cause mortality between the two groups. Conclusions. e analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin. ese findings support clinical benefit for single antiplatelet therapy with clopidogrel over aspirin for secondary prevention in patients with recent ischemic stroke.
Introduction
Stroke is the second most common cause of death and the third most common cause of disability worldwide [1] . Approximately 795,000 people in the United States experience a stroke each
year, of which 87% are ischemic strokes [2] . Additionally, approximately 20% of patients with a primary diagnosis of stroke have a second stroke within two years, accounting for 185,000 annual cases in the United States [2, 3] . ose with recurrent strokes have higher costs per patient and are more likely to experience poor outcomes as compared to patients with primary stroke [2, [4] [5] [6] . erefore, secondary stroke prevention in patients with a history of ischemic stroke is critical in reducing the overall burden of stroke. It is estimated that nearly 80% of secondary strokes can be prevented with antiplatelet therapy when combined with lifestyle changes [2, 7] .
Current guidelines from the American Heart Association and American Stroke Association recommend antiplatelet therapy with aspirin for patients with ischemic stroke [7, 8] . Other approved antiplatelet treatment options including clopidogrel, aspirin/dipyridamole, and ticlopidine have been shown to be safe and effective for secondary prevention in this population, however, the relative safety and effectiveness among the different antiplatelet agents has still not been clearly established [9] [10] [11] [12] [13] . Dual antiplatelet therapy with clopidogrel in combination with aspirin has been compared to aspirin in reducing recurrent stroke in patients with minor stroke (within 12-24 hours from onset) or transient ischemic attack (TIA) [14, 15] , but data on the efficacy and safety of clopidogrel compared to aspirin as single antiplatelet agents exclusively in patients with recent ischemic stroke is limited. e aim of this study was to conduct a systematic review and meta-analysis to compare the efficacy and safety of clopidogrel versus aspirin used as a monotherapy for secondary prevention in patients with recent ischemic stroke. Findings from this comprehensive update on the available body of evidence will guide healthcare professionals and decision makers on the selection of optimal antiplatelet agent for preventative use in patients with recent ischemic stroke. [16] . To ensure that potentially relevant studies were not overlooked, reference lists from other reviews and meta-analyses on the current topic were searched by hand. e Preferred Reporting Items for Systematic review and Meta-Analysis protocols (PRISMA) guidelines were followed [17] .
Methods

Study Selection.
Medical librarians screened titles and abstracts based on a standardized review protocol that defined study eligibility criteria using the PICOTSS format, which outlines the participants, interventions, comparators, outcomes, timing, setting, and study designs of interest (Table  1) . Eligible studies were those that compared the beneficial and harmful effects of clopidogrel and aspirin monotherapies for the prevention of recurrent stroke and other cardiovascular complications in patients who experienced ischemic stroke in the previous year. Studies that also enrolled patients with TIA were included only if data for ischemic stroke patients were reported separately. Randomized controlled trials (RCT) and comparative observational studies with at least 1-month follow-up were included. ere was no restriction for study setting. Studies were required to report at least one outcome of interest.
Efficacy outcomes included recurrent stroke of any type, recurrent ischemic stroke, and all-cause mortality. Also collected were major adverse cardiovascular and cerebrovascular events (MACCE). MACCE was defined as a composite outcome that included two or more of the following: recurrent stroke, myocardial infarction, unstable angina, coronary revascularization, aortic aneurysm rupture, peripheral artery Studies presented only in conference abstracts without an associated publication were excluded, as this data is not peer reviewed and there is o en limited information available on the details of the study and patient characteristics. A PRISMA flow diagram was created based on the search results and study selection.
Data Extraction and Quality Assessment.
Relevant information was extracted by two independent reviewers using the Doctor Evidence so ware platform version 2.0 [16] . e following information was collected: study design, study location, publication year, number of patients in each arm, intervention, comorbidities, outcomes of interest, and study inclusion/exclusion criteria. When available, the definitions and descriptions of stroke and outcomes provided by the authors were also captured. Any discrepancies in data extraction were resolved by discussion. All terms (characteristics and outcomes) were collected as reported by study authors and synonyms were "bound" before analysis using the DOC™ Ontology System. Detailed methods are described elsewhere [16] . Quality assessment of the included studies was performed by two independent reviewers using the Cochrane Collaboration tool for assessing the risk of bias for randomized trials and the Newcastle-Ottawa Scale for cohort studies [18, 19] .
Statistical Analysis.
Pairwise meta-analysis for outcomes were performed using the inverse-variance weighted random effects model based on the DerSimonian and Laird 1986 method to estimate the risk ratio (RR) and 95% confidence interval (CI) [20] . A random effects model took into account both within-study and between-study variability. Heterogeneity was assessed using the -squared ( 2 ) statistic, which describes the percentage of variation across the studies that is due to heterogeneity rather than chance [21] . Percentages of approximately 25%, 50%, and 75% were considered to have low, moderate, or high heterogeneity, respectively. Patient and 
Quality
Assessment. e quality assessment for the included studies is presented in Supplemental Table II . e risk of bias was rated as low for all seven domains for the RCT. All of the observational studies were rated as of high quality, with Newcastle Ottawa Scale scores of eight or nine. e 2 statistic for each outcome is shown in Figures 2 and 3.
Study and Patient Characteristics.
One RCT and four retrospective cohort studies met the PICO criteria for inclusion. Study and patient characteristics of the studies are shown in Table 2 . All retrospective cohort studies were conducted in a single country (Denmark, Greece, and Taiwan), whereas the RCT was conducted across 16 countries. All studies were published in peer-reviewed journals.
A total of 29,357 adult patients who had recent ischemic stroke received either clopidogrel (푛 = 14, 293) or aspirin (푛 = 15, 064) for secondary prevention. e proportion of males ranged from 48% to 73%. e mean age ranged from 64.5 years to 77.6 years. e length of study follow-up ranged from one year to five years. Comorbidities such as diabetes, hypertension, hyperlipidemia, coronary artery disease, myocardial infarction, congestive heart failure, and peripheral artery disease were prevalent at baseline ( Table 2) . ere was study characteristics were visually assessed for any potential heterogeneity across studies that might have affected pooled effect estimates. Publication bias could not be assessed due to the limited number of studies available for all outcomes. Multiple analyses were also conducted to consider varying definitions for the composite MACCE outcome in the event that studies reported more than one composite outcome that could qualify as MACCE. If a study reported multiple composite vascular outcomes, the most inclusive composite outcome was selected for the main analysis [22] . All analyses were performed on DOC™ Data, using R (metaphor package [v.2.0.0]) [23] .
Results
Literature Search.
Of the 2,790 records identified in our search, 2,742 were excluded through title and abstract screening. One additional study was identified manually a er the initial search [24] . Among the 48 full texts reviewed, six studies met eligibility criteria ( Figure 1 ). One paper [21] reported on diabetic patients for the same retrospective cohort [22] and was therefore excluded, resulting in a total of five studies included in the meta-analysis. Cardiovascular erapeutics 6 may underestimate the true preventative effects of clopidogrel.
Bleeding event data was only available from retrospective cohort studies. Any reported bleeding events including both composite bleeding events and specific bleeding events were combined (e.g., intracranial hemorrhage and gastrointestinal bleeding). ese bleeding events were captured from insurance databases or national registries, and it is reasonable to assume that these events were severe enough to require medical attention (e.g., office visit or hospitalization). However, due to the nature of the claim-based database and national registries, we were unable to compare bleeding events by severity. In one study [22] , the authors noted that clopidogrel was prescribed only for those with pre-existing gastrointestinal ulcers or bleeding issues or for those who have already failed on aspirin.
is is important to note as the results may not reflect the true rate of bleeding events associated with clopidogrel use.
Selecting optimal therapy for secondary stroke prevention requires careful attention, as these patients o en present with comorbidities and other risk factors which may influence prescription and treatment effectiveness. e boxed label warning for clopidogrel cautions against use of clopidogrel in patients with impaired platelet reactivity due to known genetic polymorphisms of CYP2C19 [28] . e majority of studies in this review included data from before 2010 and genotype testing or platelet monitoring via platelet function tests may not have been performed, as routine testing is still not included in any current guideline recommendations. e included observational studies used claim-based or registry data, and in such real-world settings, the selection of antiplatelets was based on physicians' preference and receipt of clopidogrel o en depended on insurance or drug formularies and requirements by country. However, this information was not reported in the studies. Due to the nature of the retrospective cohort studies included in this analysis, clinicians should be aware that unknown and therefore unmeasured confounders might have affected our effect estimates differentially.
Aspirin remains the recommended antiplatelet therapy for patients with ischemic stroke in current guidelines [8] .
Published trial data suggests clopidogrel as single antiplatelet therapy is safe and effective for secondary prevention compared to aspirin and the combination of aspirin/dipyridamole [27, 29] . However, the strength of the evidence in support of clopidogrel over other antiplatelet agents is limited by the few numbers of studies that make direct comparison to clopidogrel as single antiplatelet therapy, and more recent data is based on the combination of clopidogrel and aspirin in mixed populations with ischemic stroke or TIA. In the absence of further clinical trials, indirect evidence obtained through further meta-analysis and data from prospective patient registries may provide valuable insights on the efficacy and safety of clopidogrel relative to aspirin for secondary prevention patients with ischemic stroke.
To our knowledge, this is the first systematic review and meta-analysis conducted in patients with recent ischemic stroke specifically, as most of the current evidence is based on stroke and TIA populations. We included all published clinical trials and observational studies that made direct comparison of clopidogrel and aspirin monotherapy for secondary no observed trend in different patient characteristics between two treatment groups upon inspection. Two studies did not enroll patients with a history of atrial fibrillation [22, 25] and three studies did not enroll patients who had received anticoagulation therapy [24] [25] [26] . e average daily dose of clopidogrel was similar across the studies that reported the average daily dose (~75 mg/day), whereas the average daily dosage of aspirin varied from 102 mg/day to 325 mg/day. e reported outcome definitions varied across studies, most notably for MACCE and bleeding events ( Supplemental  Table III ).
Comparative Efficacy and Effectiveness.
Results of the pairwise meta-analysis showed a statistically significantly lower risk of MACCE among patients who received clopidogrel compared to those who received aspirin (RR 0.77 [95% CI, 0.63, 0.95]; Figure 2(a) ). e risks of stroke of any type, ischemic or hemorrhagic, (0.76 [0.58, 0.99]; Figure 2(b) ), and recurrent ischemic stroke (0.72 [0.55, 0.94]; Figure 2 (c)) were statistically significantly lower with clopidogrel therapy. ere was no difference found for the rate of all-cause mortality (Figure 2(d) ).
Sensitivity analysis using a more restrictive definition for MACCE reported in Lee et al. 2014 (i.e., ischemic or hemorrhagic stroke or MI) showed a similar result; patients receiving clopidogrel experienced a lower rate of MACCE (0.72 [0.47, 0.78]) compared to aspirin ( Supplemental Table IV and Supplemental Figure I) .
Safety.
Bleeding events were reported in three studies ( Supplemental Table V ). Statistically significant reduction in risk of bleeding events was shown for clopidogrel (0.57 [0.45, 0.74]) compared to aspirin (Figure 3 ).
Discussion
e results of our review suggest clinical benefit for single antiplatelet therapy with clopidogrel over aspirin in recent ischemic stroke patients. Pooled relative risk estimates for major composite cardiovascular and cerebrovascular events, recurrence of ischemic stroke, or any ischemic or hemorrhagic stroke were all significantly lower for clopidogrel monotherapy compared to aspirin. Risk of bleeding events were also significantly lower with clopidogrel therapy.
Although broad searches were conducted to identify and include all available literature and sensitivity analyses were run to test the robustness of our findings, there are some limitations to be considered when interpreting these results. Studies o en reported composite outcomes as their primary outcome because a smaller sample size is required to adequately power a composite outcome as compared to individual outcomes. Definitions of MACCE and recurrent stroke that most closely resembled the definitions reported in other studies were used, but data collection was limited to the published study-level results. e between-study heterogeneity found in our analyses remain unexplained due to the nature of observational studies. us, the pooled preventative effects of clopidogrel over aspirin shown for MACCE and recurrent stroke Only subgroup of patients with ischemic stroke at baseline are presented. ‡ e Taiwan National Health Insurance Bureau provided reimbursement for the use of clopidogrel in patients with ischemic stroke who are allergic to aspirin, have peptic ulcer, or aspirin treatment failure. CAD: coronary artery disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; CT: computed tomography; CVA: cerebrovascular attack; IHD: ischemic heart disease; MRI: magnetic resonance imaging; PAD: peripheral artery disease; RCT: randomized controlled trial; RIND: reversible ischemic neurological deficit; TIA: transient ischemic attack.
Supplementary Materials
e supplementary PDF includes summaries of the search strings, in addition to further information on methodology and results. (Supplementary Materials) prevention in patients with ischemic stroke. Data from observational studies were included to explore the benefits and harms for this population in the real-world setting. Because there is limited data on the relative efficacy and safety of clopidogrel compared to aspirin alone, these findings can add valuable information to help clinicians and policymakers in selection of antiplatelet therapy for secondary prevention following recent ischemic stroke.
Conclusions
is systematic review and meta-analysis found that clopidogrel monotherapy was associated with significantly lower risks of MACCE, recurrent stroke, and bleeding events compared to aspirin in patients with ischemic stroke. e results of the analysis support clinical benefit for single antiplatelet therapy with clopidogrel over aspirin for secondary prevention in patients with recent ischemic stroke. ere were few studies included in this review and data were based largely on retrospective observational data. More longitudinal data and high-quality studies are warranted to verify the findings of this systematic literature review and meta-analysis.
